Literature DB >> 24641181

Host-directed therapy of tuberculosis: what is in it for microRNA?

Marco Iannaccone1, Anca Dorhoi, Stefan H E Kaufmann.   

Abstract

Tuberculosis (TB) is a major health threat and current intervention measures are far from satisfactory. MicroRNAs (miRs) have become major targets of investigations for different diseases due to their propensity to regulate gene expression in various biological processes. More recently, miRs have been found to play key roles in the control of infectious diseases. Consequently, the potential of miRs for diagnosis and therapy of TB is being considered. In this editorial, we discuss most recent lines of evidence for regulation of the immune response in TB by miRs that could form the basis for diagnosis and host-directed therapy in adjunct to canonical intervention measures in TB.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24641181     DOI: 10.1517/14728222.2014.897696

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  15 in total

1.  Host-directed drug therapy for tuberculosis.

Authors:  Reto Guler; Frank Brombacher
Journal:  Nat Chem Biol       Date:  2015-10       Impact factor: 15.040

2.  High serum miR-183 level is associated with the bioactivity of macrophage derived from tuberculosis patients.

Authors:  Chunxiao Zhang; Qingjiang Wang; Xiue Xi; Junhua Jiao; Weihua Xu; Jian Huang; Zhonghai Lai
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 3.  Host-Directed Therapies for Tuberculosis.

Authors:  David M Tobin
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-18       Impact factor: 6.915

4.  The association between serum miR-155 and natural killer cells from tuberculosis patients.

Authors:  Chunxiao Zhang; Xiue Xi; Qingjiang Wang; Junhua Jiao; Ligong Zhang; Huayang Zhao; Zhonghai Lai
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 5.  The human immune response to tuberculosis and its treatment: a view from the blood.

Authors:  Jacqueline M Cliff; Stefan H E Kaufmann; Helen McShane; Paul van Helden; Anne O'Garra
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

6.  Targeting Batf2 for infectious diseases and cancer.

Authors:  Reto Guler; Sugata Roy; Harukazu Suzuki; Frank Brombacher
Journal:  Oncotarget       Date:  2015-09-29

Review 7.  Host-targeted therapy for tuberculosis: Time to revisit the concept.

Authors:  Prabha Desikan; Aseem Rangnekar
Journal:  Indian J Med Res       Date:  2018-03       Impact factor: 2.375

Review 8.  A review of clinical models for the evaluation of human TB vaccines.

Authors:  Matthew K O'Shea; Helen McShane
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

9.  Mycobacterium tuberculosis Exploits a Molecular Off Switch of the Immune System for Intracellular Survival.

Authors:  Ulrich von Both; Maurice Berk; Paul-Michael Agapow; Joseph D Wright; Anna Git; Melissa Shea Hamilton; Greg Goldgof; Nazneen Siddiqui; Evangelos Bellos; Victoria J Wright; Lachlan J Coin; Sandra M Newton; Michael Levin
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

Review 10.  Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.

Authors:  Nelita du Plessis; Leigh A Kotze; Vinzeigh Leukes; Gerhard Walzl
Journal:  Front Cell Infect Microbiol       Date:  2018-09-21       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.